Form 4: ProMIS Neurosciences Director Acquires Options in Company
SEC Form 4 Filing
Josh Mandel-Brehm, a director of ProMIS Neurosciences Inc., acquired options to purchase 40,000 common shares of the company on October 3, 2024.
Summary
- On October 3, 2024, Josh Mandel-Brehm, a director of ProMIS Neurosciences Inc., acquired options to purchase 40,000 common shares.
- The exercise price of the options is $1.11.
- 33% of the options vested immediately on October 3, 2024, with the remaining balance vesting ratably over the next 24 months, contingent upon continued service.
- The options expire on October 3, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 10/03/2024 | Date of earliest transaction: Director acquired options to purchase 40,000 common shares; 33% of the options vested. |
| 10/03/2034 | Expiration date of the options. |
| 10/07/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.